PMID- 10867341
OWN - NLM
STAT- MEDLINE
DCOM- 20000810
LR  - 20220331
IS  - 1053-2498 (Print)
IS  - 1053-2498 (Linking)
VI  - 19
IP  - 6
DP  - 2000 Jun
TI  - Predictors of quality of life in women with heart failure. SOLVD Investigators. 
      Studies of Left Ventricular Dysfunction.
PG  - 598-608
AB  - BACKGROUND: Two and one half million women have heart failure (HF). Yet little is 
      known about quality of life (QOL) in this population and the factors influencing 
      it. Given the importance of QOL as an outcome of care, we conducted a study to 
      evaluate predictors of QOL in women with HF. METHODS: Using baseline QOL data 
      collected in the Studies of Left Ventricular Dysfunction (SOLVD) trials, we 
      studied predictors of QOL in 691 women with HF. Univariate, bivariate, and 
      multiple regression analyses were used. Potential predictors included age, 
      education, tobacco use, social isolation, life stresses, comorbidity index, New 
      York Heart Association (NYHA) class, HF symptoms, etiology, and medications. We 
      measured global QOL and QOL dimensions of physical function, emotional distress, 
      and social and general health. RESULTS: Women were older (61+/-10.5 years), 
      predominantly Caucasian (75%), and their mean ejection fraction was 0.27 
      (+/-6.51). Variables with the strongest relationship to QOL included dyspnea, 
      NYHA class, and life stresses. As dyspnea, life stresses, and NYHA class 
      increased, QOL decreased. Additionally, smoking behavior and vasodilator use was 
      associated with decreased QOL. Heart failure etiology of ischemic origin was 
      associated with decreased social life satisfaction, and use of digitalis was 
      predictive of increased social life satisfaction. Finally, increasing age was 
      related to an increase in general life satisfaction. CONCLUSION: Symptom 
      amelioration, which may improve functional ability, has the greatest potential 
      for increasing QOL in women with HF. Programs to increase physical activity in 
      women with HF should be developed and tested. Finally, clinicians may need to 
      optimize HF medications in women.
FAU - Riedinger, M S
AU  - Riedinger MS
AD  - Cedars-Sinai Medical Center, Los Angeles, California, USA. riedinger@cshs.org
FAU - Dracup, K A
AU  - Dracup KA
FAU - Brecht, M L
AU  - Brecht ML
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
SB  - IM
MH  - Clinical Trials as Topic
MH  - Female
MH  - Heart Failure/physiopathology/*psychology
MH  - Humans
MH  - Middle Aged
MH  - Prognosis
MH  - *Quality of Life
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - *Women's Health
EDAT- 2000/06/27 11:00
MHDA- 2000/08/12 11:00
CRDT- 2000/06/27 11:00
PHST- 2000/06/27 11:00 [pubmed]
PHST- 2000/08/12 11:00 [medline]
PHST- 2000/06/27 11:00 [entrez]
AID - S1053249800001170 [pii]
AID - 10.1016/s1053-2498(00)00117-0 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2000 Jun;19(6):598-608. doi: 
      10.1016/s1053-2498(00)00117-0.